The following information is intended as a resource for journalists only and was factually correct at the time it was issued.
Lisa Maguire
Director, Communications and Patient
Relations
Australia and New Zealand
+ 61 499 200 550
lisa.maguire@abbvie.com
Kate Richards
Head of Corporate Communications
Australia
and New Zealand
+61 466 420 739
kate.richards@abbvie.com
AbbVie Australia follows Medicines Australia’s Code of Conduct and the Therapeutic Goods Act. Both prohibit a pharmaceutical company from direct to consumer advertising which includes issuing media statements about our prescription medicines. We can issue statements to advise registration of a new medicine, a reimbursement notice of a medicine or news not related to our medicines.
AbbVie Australia - Local Response to COVID-19
Read here.
AbbVie welcomes Therapeutic Goods Administration (TGA) Regulatory
Approval of RINVOQ® (upadacitinib)
Read full media release here.
Chris Stemple Appointed General Manager AbbVie ANZ
Read full media release here.
New biologic option for severe plaque psoriasis now available on
Pharmaceutical Benefits Scheme
Read full media release here.
AbbVie welcomes Therapeutic Goods Administration (TGA) Regulatory
Approval of SKYRIZI™ (risankizumab)
Read full media release here.
AbbVie ANZ Appoints New Medical Director
Read full media release here.
New targeted treatment option for patients with Chronic Lymphocytic
Leukaemia (CLL) now available on the Pharmaceutical Benefits Scheme
Read full media release here.
AbbVie Welcomes TGA Regulatory Approval of VENCLEXTA® (venetoclax
tablets) in Combination with Rituximab
Read full media release here.
Eight-week Hepatitis C Treatment on Pharmaceutical
Benefits scheme from 1st August 2018
Read full media release here.
Announcement: Venclexta PBS Status
Read full media release here.
Experts concerned Parksinon’s patients may be missing out on
support in the Illawarra
Read full media release here.